Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Recalcitrant and recurrent tinea: Lessons from an international survey","authors":"Arnaud Jabet, Gentiane Monsel","doi":"10.1111/jdv.20685","DOIUrl":"https://doi.org/10.1111/jdv.20685","url":null,"abstract":"<p>We have read with great interest the article by Khan et al.,<span><sup>1</sup></span> which presents the results of an international survey conducted among dermatologists on the occurrence of recalcitrant or recurrent tinea of glabrous skin. The survey, carried out between February 2022 and July 2023, focussed on cases diagnosed over the past 3 years. It complements a previous survey that was limited to the European continent, which was consequently excluded from this article.</p><p>While non-microbiological causes of treatment failure and antifungal resistance in species such as <i>Trichophyton rubrum</i> should not be overlooked, <i>Trichophyton indotineae</i> is likely the predominant cause of treatment failure on a global scale. Since the mid-2010s, Indian dermatologists have reported a rise in recalcitrant and recurrent tinea cases linked to <i>T. mentagrophytes</i> complex isolates, later reclassified as <i>T. indotineae</i>.<span><sup>2</sup></span> This fungus has now been described across all continents.<span><sup>2-4</sup></span> In India, resistance to terbinafine has been documented in up to 75.0% of isolates, while high minimum inhibitory concentrations to azoles are observed in approximately 25.0% of cases.<span><sup>5</sup></span></p><p>Several key points in the study by Khan et al. caught our attention.</p><p>A striking finding is that the vast majority of surveyed dermatologists reported encountering recalcitrant tinea. As expected, 93% of Indian dermatologists noted such cases; however, 86.3% of non-Indian dermatologists did as well, with 42.6% reporting more than 20 cases. These figures strongly suggest that recalcitrant tinea is a global health concern warranting close attention.</p><p>Dermatologists reporting the highest numbers of recalcitrant tinea cases were primarily based in India, neighbouring South Asian countries, and Middle Eastern nations—from Israel and Lebanon to the Persian Gulf. This supports the hypothesis that <i>T. indotineae</i> is widely distributed across the Middle East, where it was already well-documented as early as 2008–2010 in Iran and subsequently in Iraq.<span><sup>2</sup></span></p><p>Interestingly, Mexico was also among the countries where dermatologists reported having seen a high number of cases. Currently, very little data are available on <i>T. indotineae</i> in Latin America. A noteworthy case was reported in Argentina, involving a patient who likely contracted the infection in Mexico, raising questions about the circulation of the dermatophyte in the region.<span><sup>3</sup></span></p><p>Data on <i>T. indotineae</i> in Africa are also extremely limited,<span><sup>4</sup></span> and only a small number of African countries participated in this survey. Given the relative scarcity of data compared with other regions—along with the potential for widespread dissemination due to hot climates and healthcare disparities—Latin American and African countries should be prioritized for epidemiologi","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1078-1079"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20685","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etrasimod for alopecia areata: The scenario for a less extensive and moderate form","authors":"M. Starace","doi":"10.1111/jdv.20693","DOIUrl":"https://doi.org/10.1111/jdv.20693","url":null,"abstract":"<p>The scenario of treatment of alopecia areata (AA) has changed in the last years; thanks to the development of a new category of drugs named Janus Kinase inhibitors (JAKi) addressed in patients with severe forms of AA who are non-responders to first-line therapy.<span><sup>1</sup></span> New molecules and drugs are approved in Phase 2/3 of clinical trials in patients with severe AA. Approved JAKi by the United States, European Union, Canada, China and Japan, with robust clinical trial data and peer-reviewed publications, are baricitinib, a JAK1/2 inhibitor, in adult patients,<span><sup>2</sup></span> and ritlecitinib, a selective dual inhibitor of JAK3 and all five members of the TEC family kinases, for adolescents (aged 12–17 years) and adult patients.<span><sup>3</sup></span> Looking at this scenario of AA, there are still no approved indications for the less extensive and moderate form (Severity of Alopecia Tool [SALT] < 50) of the disease.</p><p>I read with great interest the article by King B and colleagues.<span><sup>4</sup></span> The authors have conducted a Phase 2 randomized, double-blind, placebo-controlled trial for 52 weeks divided into a 24-week double-blind and a 28-week open-label extension period. The objectives were to evaluate the efficacy and safety of etrasimod in adult patients with moderate to severe AA. The drug studied is etrasimod, a daily oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulators. This drug has already been approved in patients with ulcerative colitis, but there are many ongoing studies on other inflammatory diseases including AA. The included patients were enrolled in two cohorts with different SALT values: In cohort 1, the randomization was 2:1 to etrasimod 2 mg or placebo of patients with SALT ≥50; in cohort 2, the randomization was 4:1:2 to etrasimod 3, 2 mg or placebo in patients with SALT ≥25 to <95.</p><p>The primary endpoint was to evaluate any modification of the percent of the SALT from baseline in each group with different dosages or placebo, and the secondary endpoint was an absolute change from the baseline of the SALT score at Week 24. In addition, the study considered the proportion of patients with ≥30% (SALT<sub>30</sub>), ≥50% (SALT<sub>50</sub>) and ≥75% (SALT<sub>75</sub>) improvement from baseline in the SALT score at Week 24. The treatment-emergent adverse events (TEAEs) were mild and present in 74.7% with two cases of discontinuation.</p><p>The conclusions of this study were as follows<span><sup>1</sup></span>: the primary and secondary efficacy endpoints have not been achieved, showing no statistically significant results. At Week 24, the least squares mean showed the per cent of the SALT from baseline of the etrasimod 2 mg, 3 mg and placebo groups −13.8, −21.4 and 0.35, respectively. The least squares mean difference (95% CI; <i>p</i> value) in SALT score %CFB of etrasimod 2 and 3 mg versus placebo was −14.1 (−38.9 to 10.6; <i>p</i> = 0.2579) and − 21.8 (−44.","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1076-1077"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20693","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor’s Picks June 2025","authors":"","doi":"10.1111/jdv.20692","DOIUrl":"https://doi.org/10.1111/jdv.20692","url":null,"abstract":"<p></p><p>Sarah Walsh</p><p>This issue is a veritable cornucopia of cutting-edge research in the domain of therapeutics of hair loss. De novo cohort results from a large trial of ritlecitinib treatment in alopecia areata (AA) are reassuring and provide valuable clinical guidance on timing, specifically ‘when’ and ‘for how long’ we should be employing these agents. Early use in the disease course, when Severity of Alopecia Tool (SALT) scores are lower, seems to predict for more favourable response (Figure 1). Moreover, continued improvement is seen up to 24 months, an important observation to inform when setting up patient expectations and pre-treatment counselling.</p><p>Tziotzios C, Sinclair R, Lesiak A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. <i>J Eur Acad Dermatol Venereol</i> 2025; <b>39</b>: 1152–1162. 10.1111/jdv.20526.</p><p>The microbiome in inflammatory skin disease has become a focus of research in recent years, and Nørreslet and colleagues' study adds further to our knowledge of the interplay between both in hand eczema. Two-week treatment of lesional skin with topical corticosteroid (TCS) led to reduced abundance of staphylococcal species, particularly <i>S. aureus</i>, and a microbiome composition closer to that of non-lesional skin (Figure 2). The authors comment that restoration of barrier function in lesional skin with TCS alone, without recourse to antimicrobials, can be sufficient to lower staphylococcal burden. In an era of antimicrobial resistance, this constitutes an important clinical finding.</p><p>Nørreslet LB, Ingham AC, Agner T, et al. Hand eczema and changes in the skin microbiome after 2 weeks of topical corticosteroid treatment. <i>J Eur Acad Dermatol Venereol</i> 2025; <b>39</b>: 1118–1125. 10.1111/jdv.20366.</p><p>Dermatologists are adept at repurposing existing drugs for use in diseases where targeted therapy is lacking. Successful use of upadacitinib, currently licenced for atopic eczema, is described by Soura et al. in a case of refractory pemphigus foliaceus (Figure 3). King et al. review bimatoprost, a prostaglandin analogue used for glaucoma, in the management of vitiligo. JAK inhibitors are present in the epidermis and may be implicated in the pathogenesis of autoimmune blistering disease, while bimatoprost induces melanogenesis. Indeed, knowledge of both the underlying mechanism of the disease and understanding of the pharmacology of the drug allows the clinician to innovate therapeutically.</p><p>King A, Sood S, Li MK. Bimatoprost for the management of vitiligo: a systematic review and meta-analysis. <i>J Eur Acad Dermatol Venereol</i> 2025; <b>39</b>: e508–e510. 10.1111/jdv.20458.</p><p>Soura E, Gerochristou M, Douvali T, et al. Treatment of pemphigus foliaceus with upadacitinib. <i>J Eur Acad Dermatol Venereol</i> 2025; <b>39</b>: e467–e469. 10.1111/jdv.20423","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1065-1067"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20692","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Doxycycline for sexually transmitted infections' prevention: Balancing promise and public health concerns","authors":"Dimitra Koumaki, Electra Nicolaidou","doi":"10.1111/jdv.20690","DOIUrl":"https://doi.org/10.1111/jdv.20690","url":null,"abstract":"<p>The continuing rise in the incidence of sexually transmitted infections (STIs) poses a significant public health challenge and necessitates novel prevention strategies to curb their spread. One such strategy could be the use of doxycycline as both pre-exposure (Doxy-PrEP) and post-exposure prophylaxis (Doxy-PEP).</p><p>The review by Stratman and Zampella<span><sup>1</sup></span> in the present issue explores the potential of Doxy-PrEP and Doxy-PEP against bacterial STIs. Concerning Doxy-Prep, there is only limited evidence from two studies in small groups of men who have sex with men (MSM) and transgender women, with mixed outcomes. Doxy-PEP has been assessed in three trials among MSM that revealed promising efficacy in reducing the incidence of syphilis and chlamydia, while the effect on gonorrhea was more modest. For example, the DOXYVAC study reported an 83.5% reduction in chlamydia and syphilis and a 33.5% drop in gonorrhea among MSM utilizing Doxy-PEP, suggesting that targeted interventions could be effective in high-risk populations.<span><sup>2</sup></span> However, the efficacy of Doxy-PEP among other populations, such as cisgender women, remains unclear, as evidenced by a study in Kenya that found no significant benefits in this population.<span><sup>3</sup></span> Nonadherence as well as biologic differences could be explored as potential explanations for this lack of efficacy, raising concerns about the generalizability of Doxy-PEP beyond MSM.</p><p>A critical concern about the broad use of Doxy-PEP emphasized by Stratman and Zampella<span><sup>1</sup></span> is the facilitation of antimicrobial resistance, especially for <i>Neisseria gonorrhoeae</i> strains. Increased antibiotic exposure could accelerate selective pressure on bacterial populations, affecting not only STI-causing pathogens but also other common bacterial pathogens (e.g. <i>Staphylococcus aureus</i>) and commensal flora, leading to broader antimicrobial resistance concerns.<span><sup>4</sup></span> These risks underscore the need for cautious implementation and robust surveillance mechanisms to assess resistance patterns and inform clinical guidelines.</p><p>In addition to scientific and clinical challenges, integrating Doxy-PEP into public health programmes presents logistical and ethical dilemmas, particularly in determining standardized protocols for patient selection, adherence monitoring, and resistance tracking. Current recommendations from the European branch of the International Union of Sexually Transmitted Infections (IUSTI)<span><sup>5</sup></span> and other health organizations advocate for a shared decision-making approach in prescribing Doxy-PEP to MSM and transgender women at high risk, yet there is no consensus on universal guidelines, raising questions about equitable access and resource allocation in lower-income settings where STIs prevention measures are already insufficient. Ethical concerns surrounding Doxy-PEP access further complicate its impl","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1068-1069"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20690","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alopecia areata and ritlecitinib: Unravelling response trajectories","authors":"Julien Seneschal","doi":"10.1111/jdv.20686","DOIUrl":"https://doi.org/10.1111/jdv.20686","url":null,"abstract":"<p>Alopecia areata (AA) is a complex autoimmune condition characterised by non-scarring hair loss, which can progress to more extensive forms such as alopecia totalis (AT) or alopecia universalis (AU). In this issue of the JEADV, King et al. investigate the long-term response patterns to ritlecitinib, a Janus kinase (JAK3)/TEC family kinase inhibitor.<span><sup>1</sup></span> This study presents a post-hoc analysis of pooled data from the ALLEGRO-2b/3 and ALLEGRO-LT trials, evaluating response trajectories over 24 months in patients receiving ritlecitinib 50 mg daily.</p><p>A key strength of this study is its categorisation of patients into responders, non-responders, relapsers, and partial responders based on the Severity of Alopecia Tool (SALT) score. The identification of six distinct responder groups—early, middle, and late responders, as well as non-responders, partial responders, and relapsers—adds a novel contribution to the literature on AA treatment. The study found that 45.5% of patients achieved a SALT score ≤ 20, with 46.0% of responders attaining complete hair regrowth (SALT score of 0). Furthermore, 93.1% of these responders maintained their response through 24 months, underscoring the durability of ritlecitinib's therapeutic effects. Notably, 10.5% of patients responded only after more than a year of treatment, highlighting the need for prolonged therapy before evaluating efficacy.</p><p>Previous studies have examined response trajectories in AA patients treated with baricitinib (4 mg or 2 mg daily).<span><sup>2</sup></span> A post-hoc analysis using growth mixture modelling of two phase III trials categorised responders into early, gradual, and late groups based on the time required to achieve SALT30. However, that analysis was limited to a 52-week follow-up period. Both studies demonstrated that patients with a shorter disease duration and lower baseline SALT scores were more likely to achieve a clinical response. The ritlecitinib analysis further revealed that female patients were more likely to experience a favourable clinical response, a novel demographic finding in AA treatment research.</p><p>The study confirms that greater disease severity (higher SALT scores, presence of AU/AT) correlates with poorer treatment response, consistent with baricitinib studies. These findings suggest that initiating systemic JAK inhibitors before the onset of severe AA (e.g. AT/AU) may yield better outcomes for patients.</p><p>Despite these insights, future research is needed to optimise the management of severe AA cases. First, analysing response patterns in other affected areas, such as the eyebrows and eyelashes, could provide valuable predictive markers for scalp response. Additionally, reports suggest that combination therapies may accelerate hair regrowth. A small case report indicated that combining systemic steroids with baricitinib led to faster hair regrowth in severe AA patients.<span><sup>3</sup></span> Another important question is","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1074-1075"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20686","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority","authors":"David Saceda-Corralo, Sergio Vañó-Galván","doi":"10.1111/jdv.20691","DOIUrl":"https://doi.org/10.1111/jdv.20691","url":null,"abstract":"<p>We are living an exciting era in the treatment of alopecia areata (AA). The arrival of Janus kinase (JAK) inhibitors such as baricitinib and ritlecitinib is not only transforming our therapeutic approach but also, most importantly, changing patients' lives. These targeted treatments offer real hope in a disease that can have devastating psycho-emotional effects on affected patients.<span><sup>1</sup></span></p><p>In this context, the systematic review and indirect treatment comparison (ITC) by Aceituno et al.<span><sup>2</sup></span> is a timely and methodologically ambitious effort to compare the efficacy of ritlecitinib and baricitinib in severe AA, using advanced statistical approaches such as multilevel network meta-regression and matching-adjusted indirect comparisons.</p><p>One of the most encouraging takeaways from this study is that both baricitinib and ritlecitinib demonstrate strong efficacy signals, with meaningful rates of hair regrowth at Week 24. This is genuinely good news for patients and clinicians alike: we now have two therapies with proven benefit, expanding our arsenal and enabling more personalized care. These results reinforce the clinical value of JAK inhibitors in AA.</p><p>The authors found no significant difference between ritlecitinib 50 mg and baricitinib 4 mg on key endpoints, although there was a statistically significant difference favouring ritlecitinib over baricitinib 2 mg for achieving SALT ≤20. While the odds ratio data are promising, it is important to remember that when outcomes are common (>10%), odds ratios may overestimate the effect size, potentially leading to misinterpretation. In everyday practice, clinicians may perceive ORs as relative risks, which can distort the real-world impact.</p><p>It is also crucial to consider the underlying population differences. The authors acknowledge the heterogeneity between trials but miss a key point: the sample sizes differ significantly, with only 118 patients receiving ritlecitinib 50 mg (including ~27 adolescents), compared to nearly 900 adults across the baricitinib trials.<span><sup>3, 4</sup></span> The exact number of patients analysed from the clinical trials of ritlecitinib is not disclosed in the main article, which makes it more difficult to interpret the data.</p><p>Nevertheless, the study offers a valuable insight: we have two effective systemic therapies for a disease that has long been frustrating to manage. As more real-world data and long-term outcomes emerge, clinicians will be better positioned to tailor treatment based on patient-specific factors, preferences, and comorbidities.</p><p>Still, the fundamental question—what is the most effective treatment for AA?—remains unanswered. Only direct, head-to-head clinical trials can resolve this and allow for confident therapeutic decision making. Until then, studies like this help build the bridge between clinical research and practical care.</p><p>In the meantime, we should celebrate the progres","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1072-1073"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20691","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Less can be more: The case for extended dosing intervals in biologic therapy for AD","authors":"Christian Vestergaard","doi":"10.1111/jdv.20684","DOIUrl":"https://doi.org/10.1111/jdv.20684","url":null,"abstract":"<p>Atopic dermatitis (AD) is a chronic, debilitating and intensely pruritic eczematous disease. Until recently, treatment options were largely limited to topical corticosteroids and topical calcineurin inhibitors. In cases of severe and refractory disease, systemic immunosuppressants such as cyclosporine A—the only licensed systemic drug for AD—methotrexate, azathioprine, mycophenolate and short-term oral glucocorticoids were used.<span><sup>1</sup></span></p><p>The introduction of biologics targeting the interleukin (IL)-4/IL-13 pathway has revolutionized AD treatment. Dupilumab, which inhibits the IL-4 receptor-α (also part of the IL-13 receptor complex), as well as Tralokinumab and Lebrikizumab, both anti-IL-13 antibodies, have significantly expanded the therapeutic armamentarium and improved treatment efficacy.<span><sup>2</sup></span> Phases 2 and 3 clinical trials for these biologics evaluated various dosing regimens, leading to their current approval with fixed biweekly dosing intervals following an initial loading dose—Dupilumab and Tralokinumab are administered every 2 weeks, whereas Lebrikizumab transitions from biweekly dosing to a 4-week interval after 24 weeks of treatment.<span><sup>3</sup></span></p><p>However, these trials also included patients randomized to alternative dosing schedules, some of whom achieved comparable treatment success, as measured by EASI-75 (Eczema Area and Severity Index) and Investigator's Global Assessment (IGA) scores of 0 or 1.<span><sup>3</sup></span> Additionally, emerging real-world evidence suggests that certain patients may maintain disease control with extended dosing intervals, potentially optimizing treatment burden and cost-effectiveness.</p><p>The transition from classical immunomodulators to biologics has been previously described. However, individualized dosing of biologics for AD patients has received little attention until now.<span><sup>4</sup></span> The guiding principle for medication use in treating any disease or patient should be to prescribe as much as necessary but as little as possible. This approach minimizes side effects and patient discomfort while keeping treatment costs low, all while ensuring therapeutic goals are met.</p><p>In their paper, Jacobson et al.<span><sup>5</sup></span> review the literature on dosing intervals for biologics in atopic dermatitis, specifically exploring the potential for extending these intervals. Using data from the LIBERTY-AD SOLO studies (Dupilumab), ECZTRA 1 and 2 (Tralokinumab), ADVOCATE 1 and 2 (Lebrikizumab) and real-world evidence, they assess both the feasibility of prolonged dosing and the patient profiles most suitable for this approach.</p><p>Their analysis suggests that dosing intervals can be extended in up to half of patients undergoing biologic therapy. Moreover, if treatment efficacy declines, reverting to the original dosing schedule typically restores disease control. These findings could significantly impact our daily treatment ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"39 6","pages":"1070-1071"},"PeriodicalIF":8.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20684","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are we missing Mpox cases? Changes in clade IIb clinical phenotype in the post-vaccination era.","authors":"Taiana Silva Carvalho, Su Mei Goh, Luke Moore, Marcus Pond, Ruth Byrne, Joseph Heskin, Nicolo Girometti, Michael Rayment, Rachael Jones","doi":"10.1111/jdv.20746","DOIUrl":"https://doi.org/10.1111/jdv.20746","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual orientation and gender identity in clinical trials of atopic dermatitis and psoriasis.","authors":"Michael J Martinez, Corinne Rabbin-Birnbaum, Howa Yeung, John G Zampella","doi":"10.1111/jdv.20742","DOIUrl":"https://doi.org/10.1111/jdv.20742","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of adalimumab-induced psoriasis in hidradenitis suppurativa versus other inflammatory diseases.","authors":"Tung S Tran, Anh B Q Nguyen, Trang M Nguyen, Edward V Loftus, Courtney A Arment, Doanh H Le, Afsaneh Alavi, David A Wetter, Giang H Nguyen","doi":"10.1111/jdv.20743","DOIUrl":"https://doi.org/10.1111/jdv.20743","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}